Digitisation | September 02, 2023
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
With India supplying around 60% of the world's vaccine needs and 20-22% of generic exports, the country is dedicated to providing affordable, high-quality drugs and contribute to global accessibility
Global Initiative on Digital Health launched at the G2O Health Minister’s Meeting
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Subscribe To Our Newsletter & Stay Updated
